Global Cerebrospinal Fluid Management Market $2.7 Billion by 2029

The global market for cerebrospinal fluid management predicted to reach $2.7 billion by 2029, growing at a CAGR of 5.5% over the forecast period, driven by growing elderly population, and increasing demand for minimally invasive surgeries worldwide.

• Other factors driving the market growth include increasing patient awareness in developing countries and increasing incidences of brain changes associated with Alzheimer’s and Parkinson diseases.

Cerebrospinal fluid (CSF) is vital for normal brain function. Analysis of cerebrospinal fluid can provide information on diagnosis, therapeutics in certain conditions, and research opportunity into neurological disease. 

• Accurate analysis of CSF profile is essential in diagnosing and managing a variety of infectious and inflammatory conditions involving the brain, meninges, and spinal cord.
  • During recent years, numerous biomarkers for neuronal and astroglial injury, as well as disease-specific protein inclusions, have been developed for neurodegenerative disorders.
    • Basic CSF biomarkers, such as CSF/serum albumin ratio and CSF cell counts, have been used to diagnose inflammatory and infectious CNS disorders.

A more accurate understanding of normal CSF physiology and pathophysiology would lead to improved diagnostic accuracy, permit the identification of new etiological factors in a variety of diseases, and promote the development of new therapeutic approaches.

The global cerebrospinal fluid management market report provides market size estimates ($million 2019 to 2029), market share, growth trends and forecast (CAGR% 2023 to 2029). 

The global CSF market segmented by product [CSF shunts, CSF drainage system (ventricular drainage system, lumbar drainage system)], and geography.

• Based on the products, the CSF shunts segment accounted for the largest share of total CSF management market, while CSF drainage systems segment predicted to grow at the fastest CAGR during the forecast period.
  • CSF shunts are commonly employed to treat patients with hydrocephalus. They can be used for a variety of conditions including hydrocephalus, idiopathic intracranial hypertension, syrinx, and pseudomeningocoele.
  • Hydrocephalus is the most common neurosurgical condition among children worldwide. Its surgical management by means of shunt diversion of the cerebral-spinal fluid has been widely available for a long time and is considered a highly effective solution to most cases.
    • Despite of the advent, development and popularization of endoscopic techniques in the treatment of hydrocephalus, shunt technology experienced unparallel improvement during the last decades.
  • While shunt insertion remains the mainstay of treatment, neuroendoscopic interventions such as endoscopic third ventriculostomy (ETV) have proven successful for specific pathological conditions.
    • Despite the popularity of endoscopic third ventriculostomy in the neurosurgical armamentarium, most patients with hydrocephalus are still managed with the implantation of a CSF shunt in which the CSF flow is regulated by a differential-pressure valve (DPV).

The global CSF market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

• Geographically, the North America region accounted for the largest market share and also expected to remain dominant during the forecast period.
  • Increasing geriatric population, rapid innovation in technology, and high R&D expenditure are the key factors driving the growth in the developed countries.

The global CSF management report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and/or services offered, and recent trends in strategic management. 

Major competitors operating in the global cerebrospinal fluid management market and included in this report are Johnson & Johnson (DePuy Synthes), Medtronic plc, B. Braun Melsungen AG, Sophysa S.A., Spiegelberg GmbH & Co. KG, Integra LifeSciences Corporation, BeckerSmith Medical, Inc., and Möller Medical GmbH.

• Product
  • CSF Shunts
  • CSF Drainage System
    • Ventricular Drainage System
    • Lumbar Drainage System
• Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
• Company profiles
  • B. Braun Melsungen AG
  • BeckerSmith Medical, Inc.
  • Integra LifeSciences Corporation
  • Johnson & Johnson (DePuy Synthes)
  • Medtronic plc
  • Möller Medical GmbH
  • Sophysa S.A.
  • Spiegelberg GmbH & Co. KG

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/cerebrospinal-fluid-management-market/

Related publications:

• Cerebrospinal Fluid Management Market by Product (CSF Shunts), CSF Drainage Systems (Ventricular Drainage System, Lumbar Drainage System) and Forecast 2023-2029
• Global Cell Surface Markers Market $48.5 Billion by 2029
• Trends in Electronic Medical Device Technologies and Systems
• Global Hernia Repair Devices Market $11.3 Billion by 2029
• Cardiovascular Disease Management Devices Market by Product [Surgical Procedure Devices (Robotic Assisted Surgical Systems, Vascular Access Site Closure Devices), Therapeutic Cardiac Rhythm Management Devices (Pacemakers), Circulatory Disorder Management Devices (Stents, Angioplasty Catheters, Atherectomy Catheters and Devices), Embolic Protection and Embolus/Thrombus Removal Devices (Catheter-directed Thrombolysis Catheters, Others)] and Forecast 2023-2029